ERBB2 and breast cancer: Since miR-630 overexpression may restore sensitivity to HER2-targeted agents by attenuating tumor cell aggressiveness and motility, miR-630 can be regarded as a putative diagnostic and prognostic biomarker in lapatinib resistance but also as a therapeutic alternative in removing TKIs resistance in BC [100].